Barbara Hirsch, MD
Endocrinology, Diabetes & Metabolism · Manhasset, NYNPI 1679533434
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $592,828 of the $746,453 with a category attached, or 79.4%. Lilly USA, LLC accounts for 65.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $150,381 and has fallen 52.7% since, to $71,072 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,039 payments — averaging $718.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$487K
- Abbott$164K
- Novo Nordisk$67K
- Eli Lilly$7K
- Johnson & Johnson$7K
- Merck$5K
- plus $9K from 23 others
What the payments were for
- Consulting fees$39,1615%
- Speaking & faculty fees$592,82879%
- Travel & lodging$98,82013%
- Food & beverage$15,4232%
- Education$1370%
- Other$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 634 | $487,495 |
| Abbott | 215 | $163,870 |
| Novo Nordisk | 85 | $67,098 |
| Eli Lilly | 18 | $7,121 |
| Johnson & Johnson | 9 | $6,885 |
| Merck | 7 | $4,800 |
| Cequr Corporation | 1 | $3,563 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $2,528 |
| AbbVie | 10 | $2,112 |
| Amgen | 10 | $195 |
| Xeris Pharmaceuticals, Inc. | 7 | $146 |
| Sanofi-aventis U.S. LLC | 5 | $107 |
| Mannkind Corporation | 4 | $78 |
| Novartis | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| AstraZeneca(2 entities) | 3 | $50 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| Medtronic(2 entities) | 2 | $37 |
| Avvisto Therapeutics, LLC | 2 | $36 |
| Corcept Therapeutics | 1 | $26 |
| Zealand Pharma US, Inc. | 1 | $25 |
| Valeritas, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Insulet Corporation | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$221,563
- TRULICITY$195,163
- FREESTYLE LIBRE 3$77,123
- FreeStyle Libre Pro$55,584
- RYBELSUS$33,366
- FreeStyle Libre$18,251
- Ozempic$16,626
- FreeStyle Libre 2$11,530
- Tresiba$9,177
- INVOKANA$6,795
- Victoza$5,844
- STEGLATRO$4,720
- CeQur Simplicity$3,563
- CYCLOSET$2,450
- Synthroid$1,988
How this compares
$746,453 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 440 | $802,625 |
| OzempicSemaglutide | 178 | $312,838 |
| JardianceEmpagliflozin | 165 | $232,673 |
| TrulicityDulaglutide | 101 | $184,756 |
| ProliaDenosumab | 56 | $97,208 |
| GlumetzaMetformin Hcl | 14 | $94,371 |
| JanuviaSitagliptin Phosphate | 35 | $50,977 |
| RybelsusSemaglutide | 13 | $33,278 |
| SynthroidLevothyroxine Sodium | 407 | $28,389 |
| FarxigaDapagliflozin Propanediol | 17 | $27,996 |
| TradjentaLinagliptin | 16 | $22,927 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $22,464 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $20,938 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $15,362 |
| InvokanaCanagliflozin | 18 | $14,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $487,495 | $987,380541 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $67,098 | $353,429218 claims |
| AmgenProlia | $195 | $97,20856 claims |
| MerckJanuvia, Janumet Xr | $4,800 | $73,44057 claims |
| AbbVieSynthroid | $2,112 | $28,389407 claims |
| AstraZenecaFarxiga | $50 | $27,99617 claims |
| Johnson & JohnsonInvokana | $6,885 | $14,94918 claims |
| Cequr CorporationCequr Simplicity | $3,563 | $9,40521 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $7,352376 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Manhasset
- Vinay KapoorManhasset$820K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- John BilezikianNew York$809K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
- Erlin MarteBuffalo$570K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.